Clinical Trial Update: Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of Elotuzumab, CC-92480, and Dexamethasone in relapsed or refractory multiple myeloma after CD38- and BCMA-t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CC-92480
• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)

Snippet

Sponsor: Abdullah Khan | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING